Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome.
Kusunoki J, Kanatani A, Moller DE. Kusunoki J, et al. Among authors: kanatani a. Endocrine. 2006 Feb;29(1):91-100. doi: 10.1385/ENDO:29:1:91. Endocrine. 2006. PMID: 16622296 Review.
Acetyl-CoA carboxylase 1 (ACC1) and ACC2 regulate fatty acid synthesis and indirectly control fatty acid oxidation via a key product, malonyl CoA. ...AMP-activated protein kinase is a master regulator of nutrient metabolism, which controls several aspects of lipid m …
Acetyl-CoA carboxylase 1 (ACC1) and ACC2 regulate fatty acid synthesis and indirectly control fatty acid oxidation via a key product, …
NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice.
Moriya R, Shirakura T, Hirose H, Kanno T, Suzuki J, Kanatani A. Moriya R, et al. Among authors: kanatani a. Peptides. 2010 Apr;31(4):671-5. doi: 10.1016/j.peptides.2009.11.005. Epub 2009 Nov 17. Peptides. 2010. PMID: 19925840
Peptide YY (PYY)(3-36), a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion. Based on this anti-secretory effect, NPY Y2 receptor agonists may be useful as novel anti-diarrheal agents, but anti-diarrheal efficacy has yet to be …
Peptide YY (PYY)(3-36), a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion. Based on …
Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, Kanatani A. Mashiko S, et al. Among authors: kanatani a. Eur J Pharmacol. 2009 Aug 1;615(1-3):113-7. doi: 10.1016/j.ejphar.2009.05.018. Epub 2009 May 29. Eur J Pharmacol. 2009. PMID: 19482021
A single-dose of a neuropeptide Y(1) receptor antagonist (10-30 mg/kg) suppressed spontaneous food intake and reduced body weight in high-fat diet-fed C57BL/6 mice, while treatment with a neuropeptide Y(5) receptor antagonist did not significantly reduce food
A single-dose of a neuropeptide Y(1) receptor antagonist (10-30 mg/kg) suppressed spontaneous food intake and reduced body wei
Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
Moriya R, Mashiko S, Ishihara A, Takahashi T, Murai T, Ito J, Mitobe Y, Oda Z, Iwaasa H, Takehiro F, Kanatani A. Moriya R, et al. Among authors: kanatani a. Peptides. 2009 Jul;30(7):1318-22. doi: 10.1016/j.peptides.2009.04.006. Epub 2009 Apr 23. Peptides. 2009. PMID: 19394383
The present study examined and compared the effects of a Y2R agonist, PYY(3-36), and a Y5R antagonist, alone and in combination, on food intake and body weight in diet-induced obese (DIO) mice. ...These results illustrate that the combination of a Y2R agonist …
The present study examined and compared the effects of a Y2R agonist, PYY(3-36), and a Y5R antagonist, alone and in combinatio …
Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice.
Ito M, Gomori A, Suzuki J, Tsujioka S, Sasaki M, Matsuda M, Bednarek MA, Ito M, Ishihara A, Iwaasa H, Macneil DJ, Kanatani A. Ito M, et al. Among authors: kanatani a. J Endocrinol. 2008 Aug;198(2):309-15. doi: 10.1677/JOE-08-0087. Epub 2008 Jun 3. J Endocrinol. 2008. PMID: 18523032
Steatohepatitis with concomitant obese phenotypes was developed after 52-week exposure to a high-fat diet, and steatohepatitis with reduced body weight was developed by exposure to a methionine- and choline-deficient diet for 10 days. ...In conclusion, MCH1R antagon …
Steatohepatitis with concomitant obese phenotypes was developed after 52-week exposure to a high-fat diet, and steatohepatitis with r …
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, Ito J, Gomori A, Matsushita H, Takahashi T, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A. Mashiko S, et al. Among authors: kanatani a. Obesity (Silver Spring). 2008 Jul;16(7):1510-5. doi: 10.1038/oby.2008.223. Epub 2008 Apr 10. Obesity (Silver Spring). 2008. PMID: 18421274
OBJECTIVE: To further address the function of the Y5 receptor in energy homeostasis, we investigated the effects of a novel spironolactone Y5 antagonist in diet-induced obese (DIO) mice. ...The Y5 antagonist produced a fat-selective loss of body weight, and ameliora …
OBJECTIVE: To further address the function of the Y5 receptor in energy homeostasis, we investigated the effects of a novel spironola …
Metabolic impact of overexpression of liver glycogen synthase with serine-to-alanine substitutions in rat primary hepatocytes.
Kadotani A, Fujimura M, Nakamura T, Ohyama S, Harada N, Maruki H, Tamai Y, Kanatani A, Eiki J, Nagata Y. Kadotani A, et al. Among authors: kanatani a. Arch Biochem Biophys. 2007 Oct 15;466(2):283-9. doi: 10.1016/j.abb.2007.08.006. Epub 2007 Aug 22. Arch Biochem Biophys. 2007. PMID: 17880910
Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet.
Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, Hirose H, Ito M, Ishihara A, Iwaasa H, Kanatani A. Ito M, et al. Among authors: kanatani a. Hepatol Res. 2007 Jan;37(1):50-7. doi: 10.1111/j.1872-034X.2007.00008.x. Hepatol Res. 2007. PMID: 17300698
A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.
Mashiko S, Ishihara A, Iwaasa H, Sano H, Ito J, Gomori A, Oda Z, Moriya R, Matsushita H, Jitsuoka M, Okamoto O, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A. Mashiko S, et al. Among authors: kanatani a. Mol Pharmacol. 2007 Feb;71(2):602-8. doi: 10.1124/mol.106.029991. Epub 2006 Nov 14. Mol Pharmacol. 2007. PMID: 17105869
Neuropeptide Y (NPY) is thought to have a significant role in the physiological control of energy homeostasis. We recently reported that an NPY Y5 antagonist inhibits body weight gain in diet-induced obese (DIO) mice, with a moderate reduction in food intake. ...In …
Neuropeptide Y (NPY) is thought to have a significant role in the physiological control of energy homeostasis. We recently reported t …
Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.
Yoshimoto R, Miyamoto Y, Shimamura K, Ishihara A, Takahashi K, Kotani H, Chen AS, Chen HY, Macneil DJ, Kanatani A, Tokita S. Yoshimoto R, et al. Among authors: kanatani a. Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13866-71. doi: 10.1073/pnas.0506104103. Epub 2006 Sep 5. Proc Natl Acad Sci U S A. 2006. PMID: 16954192 Free PMC article.
The anorexigenic effects of imetit were associated with a reduction in histamine release, but a comparable reduction in histamine release with alpha-fluoromethylhistidine, an inhibitor of histamine synthesis, increased appetite. ...The results provide roles of H3Rs …
The anorexigenic effects of imetit were associated with a reduction in histamine release, but a comparable reduction in histam …
100 results
Jump to page
Feedback